Analystreport

Axsome Therapeutics, Inc. (NASDAQ: AXSM) had its price target raised by analysts at Cantor Fitzgerald from $131.00 to $161.00. They now have an "overweight" rating

Axsome Therapeutics, Inc.  (AXSM) 
Last axsome therapeutics, inc. earnings: 3/12 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: axsome.com